Concordia Healthcare Corp. (NASDAQ:CXRX)’s share price fell 3% during trading on Friday . The company traded as low as $17.54 and last traded at $17.60, with a volume of 165,369 shares traded. The stock had previously closed at $18.15.

A number of brokerages recently commented on CXRX. Zacks Investment Research downgraded shares of Concordia Healthcare Corp. from a “buy” rating to a “hold” rating in a research note on Monday, July 18th. TD Securities reiterated a “buy” rating and set a $37.00 target price (down previously from $45.00) on shares of Concordia Healthcare Corp. in a research note on Wednesday, June 29th. Canaccord Genuity reiterated a “buy” rating on shares of Concordia Healthcare Corp. in a research note on Sunday, June 26th. Royal Bank Of Canada reiterated an “outperform” rating and set a $73.00 target price on shares of Concordia Healthcare Corp. in a research note on Tuesday, June 21st. Finally, Goldman Sachs Group Inc. began coverage on shares of Concordia Healthcare Corp. in a research note on Monday, June 6th. They set a “neutral” rating and a $32.00 target price for the company. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Concordia Healthcare Corp. currently has an average rating of “Buy” and a consensus price target of $48.88.

The company’s 50 day moving average price is $21.20 and its 200 day moving average price is $26.61. The firm’s market capitalization is $890.23 million.

Concordia Healthcare Corp. (NASDAQ:CXRX) last issued its earnings results on Friday, May 13th. The company reported $1.35 EPS for the quarter, missing the Zacks’ consensus estimate of $1.54 by $0.19. The firm had revenue of $228.50 million for the quarter, compared to analyst estimates of $231 million. The company’s quarterly revenue was up 570.1% on a year-over-year basis. Equities analysts anticipate that Concordia Healthcare Corp. will post $6.15 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Stockholders of record on Friday, July 15th will be paid a $0.075 dividend. This represents a $0.30 dividend on an annualized basis and a dividend yield of 1.72%. The ex-dividend date is Wednesday, July 13th.

Other large investors have recently added to or reduced their stakes in the company. Swiss National Bank raised its stake in Concordia Healthcare Corp. by 26.7% in the fourth quarter. Swiss National Bank now owns 49,810 shares of the company’s stock worth $2,031,000 after buying an additional 10,510 shares during the last quarter. ProShare Advisors LLC purchased a new stake in Concordia Healthcare Corp. during the fourth quarter worth $1,671,000. Thornburg Investment Management Inc. raised its stake in Concordia Healthcare Corp. by 48.3% in the fourth quarter. Thornburg Investment Management Inc. now owns 116,235 shares of the company’s stock worth $4,746,000 after buying an additional 37,847 shares during the last quarter. Morgan Stanley raised its stake in Concordia Healthcare Corp. by 24.6% in the fourth quarter. Morgan Stanley now owns 269,768 shares of the company’s stock worth $11,015,000 after buying an additional 53,305 shares during the last quarter. Finally, Diamond Hill Capital Management Inc. raised its stake in Concordia Healthcare Corp. by 294.2% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 850,645 shares of the company’s stock worth $34,732,000 after buying an additional 634,880 shares during the last quarter.

Concordia Healthcare Corp. is a Canada-based diverse healthcare company. The Company is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments, which includes Legacy Pharmaceutical Division, Concordia Pharmaceuticals Inc, which consists of 23 products, including Nilandron, for the treatment of metastatic prostate cancer; Dibenzyline, for the treatment of pheochromocytoma; Lanoxin, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil, for the treatment of lupus and rheumatoid arthritis; Donnatal, for the treatment of irritable bowel syndrome, and Zonegran (zonisamide), for treatment of partial seizures in adults with epilepsy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.